Mrs. Dana Robison Emmons, MA, LMFT, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 11038 Highland Blvd, Highland, UT 84003 Phone: 801-655-5450 |
David Howarth Blackwell, LPC, LSAC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 11188 N 6000 W, Highland, UT 84003 Phone: 801-756-7403 |
Christy P Kane, PHD, CMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 5455 W 11000 N Ste 204, Highland, UT 84003 Phone: 385-223-0777 |
News Archive
The National Institutes of Health has reported in an Alzheimer's Disease prevention study that there was no increased cardiovascular risk seen in elderly patients taking Celebrex (400 mg daily) for up to three years.
"Malnutrition is easily neglected by parents, communities and governments," Lawrence Haddad, director of the Institute of Development Studies, writes in the Guardian's "Poverty Matters Blog," adding, "The signs are not visible until very acute, the impacts are felt long after the food and infection cycle has played out - and far beyond electoral cycles - and the causes are often mistakenly attributed to something else."
Researchers from the University of California, San Diego recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance-a primary defect in type 2 diabetes and obesity. Taking a systems biology approach, the bioengineers and medical researchers also determined how a common class of drugs for treating insulin resistance-TZDs-alter these same core pathways.
An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).
› Verified 8 days ago